Citius Pharmaceuticals, Inc. 47N.F Stock
Citius Pharmaceuticals, Inc. Price Chart
Citius Pharmaceuticals, Inc. 47N.F Financial and Trading Overview
Citius Pharmaceuticals, Inc. stock price | 0.6 EUR |
Previous Close | 1.11 EUR |
Open | 1.14 EUR |
Bid | 1.14 EUR x N/A |
Ask | 1.17 EUR x N/A |
Day's Range | 1.14 - 1.14 EUR |
52 Week Range | 0.73 - 1.48 EUR |
Volume | 271 EUR |
Avg. Volume | 212 EUR |
Market Cap | 184.94M EUR |
Beta (5Y Monthly) | 1.39014 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.21 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 7 EUR |
47N.F Valuation Measures
Enterprise Value | 147.81M EUR |
Trailing P/E | N/A |
Forward P/E | -7.5866666 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 1.8266453 |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | -4.297 |
Trading Information
Citius Pharmaceuticals, Inc. Stock Price History
Beta (5Y Monthly) | 1.39014 |
52-Week Change | 34.95% |
S&P500 52-Week Change | 20.43% |
52 Week High | 1.48 EUR |
52 Week Low | 0.73 EUR |
50-Day Moving Average | 1.18 EUR |
200-Day Moving Average | 1.11 EUR |
47N.F Share Statistics
Avg. Volume (3 month) | 212 EUR |
Avg. Daily Volume (10-Days) | 197 EUR |
Shares Outstanding | 158.86M |
Float | 146.55M |
Short Ratio | N/A |
% Held by Insiders | 8.41% |
% Held by Institutions | 11.48% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | September 30, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | September 30, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -18.53% |
Return on Equity (ttm) | -29.49% |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | N/A |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | N/A |
EBITDA | -34398480 EUR |
Net Income Avi to Common (ttm) | -30974042 EUR |
Diluted EPS (ttm) | -0.21 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 29.07M EUR |
Total Cash Per Share (mrq) | 0.18 EUR |
Total Debt (mrq) | 582.3K EUR |
Total Debt/Equity (mrq) | 0.63 EUR |
Current Ratio (mrq) | 5.62 |
Book Value Per Share (mrq) | 0.623 |
Cash Flow Statement
Operating Cash Flow (ttm) | -26721976 EUR |
Levered Free Cash Flow (ttm) | -17925896 EUR |
Profile of Citius Pharmaceuticals, Inc.
Country | Germany |
State | NJ |
City | Cranford |
Address | 11 Commerce Drive |
ZIP | 07016 |
Phone | 908 967 6677 |
Website | https://www.citiuspharma.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 21 |
Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.
Q&A For Citius Pharmaceuticals, Inc. Stock
What is a current 47N.F stock price?
Citius Pharmaceuticals, Inc. 47N.F stock price today per share is 0.6 EUR.
How to purchase Citius Pharmaceuticals, Inc. stock?
You can buy 47N.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Citius Pharmaceuticals, Inc.?
The stock symbol or ticker of Citius Pharmaceuticals, Inc. is 47N.F.
Which industry does the Citius Pharmaceuticals, Inc. company belong to?
The Citius Pharmaceuticals, Inc. industry is Biotechnology.
How many shares does Citius Pharmaceuticals, Inc. have in circulation?
The max supply of Citius Pharmaceuticals, Inc. shares is 198.75M.
What is Citius Pharmaceuticals, Inc. Price to Earnings Ratio (PE Ratio)?
Citius Pharmaceuticals, Inc. PE Ratio is now.
What was Citius Pharmaceuticals, Inc. earnings per share over the trailing 12 months (TTM)?
Citius Pharmaceuticals, Inc. EPS is -0.21 EUR over the trailing 12 months.
Which sector does the Citius Pharmaceuticals, Inc. company belong to?
The Citius Pharmaceuticals, Inc. sector is Healthcare.